HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiotherapy compared to chemotherapy as initial treatment of angiocentric centrofacial lymphoma (polymorphic reticulosis).

Abstract
Polymorphic reticulosis has recently been characterized as an angiocentric lymphoproliferative disorder of the peripheral T-lymphocytes. However, its treatment is still a matter of controversy. In order to study efficacy and toxicity of the primary treatment, we reviewed clinical features and therapeutic results in 29 patients seen at the Instituto Nacional de Cancerologia de Mexico. Nineteen patients received primary local irradiation and 10 patients primary combination chemotherapy. In the radiotherapy group, 14 (74%) patients achieved complete response, but only 4 (40%) did so in the primary chemotherapy group. Five patients in the latter group died of treatment-related complications. The 5-year actuarial survival rate was 70% in the irradiation group, while the 1-year survival rate was only 15% in the chemotherapy group. These data strongly suggest that, in polymorphic reticulosis, initial chemotherapy may be very toxic.
AuthorsP Sobrevilla-Calvo, A Meneses, P Alfaro, J P Bares, J Amador, E E Reynoso
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 32 Issue 1 Pg. 69-72 ( 1993) ISSN: 0284-186X [Print] England
PMID8466767 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • L-Lactate Dehydrogenase
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Female
  • Humans
  • L-Lactate Dehydrogenase (metabolism)
  • Lymphatic Diseases (drug therapy, mortality, radiotherapy)
  • Lymphoma, T-Cell (drug therapy, mortality, radiotherapy)
  • Male
  • Middle Aged
  • Radiotherapy Dosage
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: